Doppler echocardiographic assessment of the effects of inhaled long-acting β2-agonists on pulmonary artery pressure in COPD patients

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 3, 2007, Pages 258-264

  Cazzola, Mario ^a   Mantero, Antonio ^b   Santus, Pierachille ^b   Carlucci, Paolo ^b   Mondoni, Michele ^b   Bosotti, Laura ^b   Centanni, Stefano ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

COPD; Formoterol; Pulmonary artery pressure; Salmeterol; Transthoracic Doppler echocardiography

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; SALMETEROL;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG HEMODYNAMICS; MALE; PRIORITY JOURNAL; PULSE OXIMETRY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; AGED, 80 AND OVER; ALBUTEROL; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; MIDDLE AGED; PILOT PROJECTS; PULMONARY ARTERY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; TREATMENT OUTCOME; TRICUSPID VALVE INSUFFICIENCY;

EID: 33846924068     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.02.002     Document Type: Article

References (42)

1. Oswald-Mammosser M., Weitzenblum E., et al. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 107 (1995) 1193-1198
2. Kessler R., Faller M., Fourgaut G., et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159 (1999) 158-164
3. Barberà A., Peinado V.I., and Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 892-905
4. Adnot S., Samoyeau R., and Weitzenblum E. Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Blood Press Suppl 3 (1995) 47-57
5. Jones R., Zapol W.M., and Reid L. Pulmonary artery remodeling and pulmonary hypertension after exposure to hypoxia for 7 days. Am J Pathol 117 (1984) 273-285
6. Enson Y., Giuntini C., Lewis M.L., et al. The influence of hydrogen ion concentration and hypoxia on the pulmonary circulation. J Clin Invest 43 (1964) 1146-1162
7. Voelkel N.F., and Tuder R.M. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?. J Clin Invest 106 (2000) 733-738
8. Teule G.J., and Majid P.A. Haemodynamic effects of terbutaline in chronic obstructive airways disease. Thorax 35 (1980) 536-542
9. Jones R.M., Stockley R.A., and Bishop J.M. Early effects of intravenous terbutaline on cardiopulmonary function in chronic obstructive bronchitis and pulmonary hypertension. Thorax 37 (1982) 746-750
10. Eliasen K., Ringsted C., Munck O., et al. Pulmonary vasodilatation and augmentation of right ventricular function following terbutaline infusion in severe chronic pulmonary disease. Clin Physiol 11 (1991) 231-243
11. Ringsted C.V., Eliasen K., Andersen J.B., et al. Ventilation-perfusion distributions and central hemodynamics in chronic obstructive pulmonary disease. Effects of terbutaline administration. Chest 96 (1989) 976-983
12. Ballester E., Roca J., Ramis L., et al. Pulmonary gas exchange in severe chronic asthma. Response to 100% oxygen and salbutamol. Am Rev Respir Dis 141 (1990) 558-562
13. Galie N., Hinderliter A.L., Torbicki A., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 1380-1386
14. Sitbon O., Gressin V., Speich R., et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170 (2004) 1212-1217
15. Chockalingam A., Gnanavelu G., Venkatesan S., et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 99 (2005) 91-95
16. Richalet J.P., Gratadour P., Robach P., et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 171 (2005) 275-281
17. Celli B.R., MacNee W., Agusti A., et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
18. Higham A., Dawson D., Joshi J., et al. Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD. Eur Respir J 17 (2001) 350-355
19. Kircher B.J., Himelman R.B., and Schiller N.B. Non-invasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol 66 (1990) 493-496
20. Pepi M., Tamborini G., Galli C., et al. A new formula for echo-Doppler estimation of right ventricular systolic pressure. J Am Soc Echocardiogr 7 (1994) 20-26
21. Cecconi M., La Canna G., Manfrin M., et al. Evaluation of mean right atrial pressure by two-dimensional and Doppler echocardiography in patients with cardiac disease. G Ital Cardiol 28 (1998) 357-364
22. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 8 (1986) 307-310
23. MacNee W., Wathen C.G., Hannan W.J., et al. Effects of pirbuterol and sodium nitroprusside on pulmonary haemodynamics in hypoxic cor pulmonale. Br Med J 287 (1983) 1169-1172
24. Mols P., Ham H., Naeije N., et al. How does salbutamol improve the ventricular performance in patients with chronic obstructive pulmonary disease?. J Cardiovasc Pharmacol 12 (1988) 127-133
25. Bossone E., Duong-Wagner T.H., Paciocco G., et al. Echocardiographic features of primary pulmonary hypertension. J Am Soc Echocardiogr 12 (1999) 655-662
26. Murata I., Kihara H., Shinohara S., et al. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J 56 (1992) 983-991
27. Hinderliter A.L., Willis P.W., Barst R.J., et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension: Primary Pulmonary Hypertension Study Group. Circulation 95 (1997) 1479-1486
28. Denton C.P., Cailes J.B., Phillips G.D., et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36 (1997) 239-243
29. Kim W.R., Krowka M.J., Plevak D.J., et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 6 (2000) 453-458
30. Shapiro S.M., Oudiz R.J., Cao T., et al. Primary pulmonary hypertension: improved long term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30 (1997) 343-349
31. Shen J.Y., Chen S.L., Wu Y.X., et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 18 (1999) 147-151
32. Yock P.G., and Popp R.L. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70 (1984) 657-662
33. Currie P.J., Seward J.B., Chan K.L., et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6 (1985) 750-756
34. Chan K.L., Currie P.J., Seward J.B., et al. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J Am Coll Cardiol 9 (1987) 549-554
35. Conner M.W., and Reid L.M. Mapping of β-adrenergic receptors in rat lung: effect of isoproterenol. Exp Lung Res 6 (1984) 91-101
36. Porcelli R.J., Viau A.T., Naftchi N.E., et al. β-Receptor influence on lung vasoconstrictor responses to hypoxia and humoral agents. J Appl Physiol 43 (1977) 612-616
37. Bevan R.D. Influence of adrenergic innervation on vascular growth and mature characteristics. Am Rev Resp Dis 140 (1989) 1478-1482
38. Nijkamp F.P., Engels F., Henricks P.A., and Van Oosterrhout J.M. Mechanisms of β-adrenergic receptor regulation in lungs and its implications for physiological responses. Physiol Rev 72 (1992) 323-367
39. Sartori C., Allemann Y., Duplain H., Lepori M., Egli M., Lipp E., et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 346 (2002) 1631-1636
40. Spiekerkoetter E., Fabel H., and Hoeper M.M. Effects of inhaled salbutamol in primary pulmonary hypertension. Eur Respir J 20 (2002) 524-528
41. Gardner M.J., and Altman D.G. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J 292 (1986) 746-750
42. 2 agonists in the management of stable chronic obstructive pulmonary disease. Drugs 60 (2000) 307-320